CN109908328A - Nanometer percutaneous technique is used to improve the eye sticker and preparation method thereof of eyes xerophthalmia - Google Patents
Nanometer percutaneous technique is used to improve the eye sticker and preparation method thereof of eyes xerophthalmia Download PDFInfo
- Publication number
- CN109908328A CN109908328A CN201910225899.XA CN201910225899A CN109908328A CN 109908328 A CN109908328 A CN 109908328A CN 201910225899 A CN201910225899 A CN 201910225899A CN 109908328 A CN109908328 A CN 109908328A
- Authority
- CN
- China
- Prior art keywords
- xerophthalmia
- eye sticker
- eye
- sodium alginate
- eyes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001508 eye Anatomy 0.000 title claims abstract description 53
- 208000005494 xerophthalmia Diseases 0.000 title claims abstract description 25
- 238000000034 method Methods 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 239000000661 sodium alginate Substances 0.000 claims abstract description 21
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 21
- 238000003756 stirring Methods 0.000 claims abstract description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000007788 liquid Substances 0.000 claims abstract description 15
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 15
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 14
- 239000001110 calcium chloride Substances 0.000 claims abstract description 14
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 239000000843 powder Substances 0.000 claims abstract description 12
- 229920001661 Chitosan Polymers 0.000 claims abstract description 9
- 239000002105 nanoparticle Substances 0.000 claims abstract description 8
- 239000000243 solution Substances 0.000 claims abstract description 7
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 6
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 6
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 6
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 6
- 238000013019 agitation Methods 0.000 claims abstract description 6
- 229940116229 borneol Drugs 0.000 claims abstract description 6
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 6
- 238000005119 centrifugation Methods 0.000 claims abstract description 6
- 239000012153 distilled water Substances 0.000 claims abstract description 6
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 6
- 238000001914 filtration Methods 0.000 claims abstract description 6
- 238000004108 freeze drying Methods 0.000 claims abstract description 6
- 229940041616 menthol Drugs 0.000 claims abstract description 6
- 239000004745 nonwoven fabric Substances 0.000 claims abstract description 6
- 230000008569 process Effects 0.000 claims abstract description 6
- 230000001954 sterilising effect Effects 0.000 claims abstract description 6
- 239000011550 stock solution Substances 0.000 claims abstract description 6
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 8
- 229930105110 Cyclosporin A Natural products 0.000 claims description 8
- 244000241838 Lycium barbarum Species 0.000 claims description 7
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 7
- 235000015468 Lycium chinense Nutrition 0.000 claims description 7
- 235000013399 edible fruits Nutrition 0.000 claims description 7
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 6
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 6
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims description 6
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 6
- 229940116977 epidermal growth factor Drugs 0.000 claims description 6
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 6
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 5
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 5
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 5
- 235000012680 lutein Nutrition 0.000 claims description 5
- 229960005375 lutein Drugs 0.000 claims description 5
- 239000001656 lutein Substances 0.000 claims description 5
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims description 5
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims description 5
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims description 5
- 235000019155 vitamin A Nutrition 0.000 claims description 5
- 239000011719 vitamin A Substances 0.000 claims description 5
- 229940045997 vitamin a Drugs 0.000 claims description 5
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims description 5
- 229930003427 Vitamin E Natural products 0.000 claims description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 4
- 235000019165 vitamin E Nutrition 0.000 claims description 4
- 229940046009 vitamin E Drugs 0.000 claims description 4
- 239000011709 vitamin E Substances 0.000 claims description 4
- 239000003292 glue Substances 0.000 claims description 3
- AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 claims 1
- 239000002539 nanocarrier Substances 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 5
- 208000003464 asthenopia Diseases 0.000 abstract description 4
- 238000001727 in vivo Methods 0.000 abstract description 3
- 238000003860 storage Methods 0.000 abstract description 3
- 239000006185 dispersion Substances 0.000 abstract description 2
- 239000003814 drug Substances 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 108010036949 Cyclosporine Proteins 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- AEMOLEFTQBMNLQ-AZLKCVHYSA-N (2r,3s,4s,5s,6r)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical compound O[C@@H]1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-AZLKCVHYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-SYJWYVCOSA-N (2s,3s,4s,5s,6r)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical compound O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-SYJWYVCOSA-N 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- -1 acetylamino, amino groups Chemical group 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000607 artificial tear Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006589 gland dysfunction Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 201000010041 presbyopia Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 210000000457 tarsus Anatomy 0.000 description 1
- 230000004488 tear evaporation Effects 0.000 description 1
Abstract
The invention discloses the eye stickers and preparation method thereof that nanometer percutaneous technique is used to improve eyes xerophthalmia.Include the following steps: for sodium alginate and calcium chloride to be dissolved in distilled water respectively；Compositions useful is dissolved in sodium alginate stock solution, is stirred；Calcium chloride water is added in solution under agitation, and continues stirring and completes pregelatinized process；It dissolves chitosan in acetic acid, and is added in pregel, form nano particle；Dispersion, with centrifugation freeze-drying at powder；Above-mentioned powder is redissolved, and borneol is added and menthol stirs and evenly mixs, filtering, sterilizing obtains eye sticker liquid；Non-woven fabrics is put into eye sticker liquid and is infiltrated, the eye sticker for the xerophthalmia that is eased.Present invention uses what can be degraded in vivo, the chitin-sodium alginate nano-carrier of good biocompatibility is carried in eye sticker, the storage stability of composition is not only improved, while wherein effective component can play the effect for further improving xerophthalmia and visual fatigue with slow release.
Description
Technical field
The present invention relates to a kind of eye stickers, and in particular to nanometer percutaneous technique is used to improve the eye sticker and its system of eyes xerophthalmia
Preparation Method.
Background technique
Xerophthalmia is since the natural function and protection mechanism of external eyes generate various obstacles, and tear film is unstable when causing to twinkle
A kind of eye surface diseases.Generally acknowledged xerophthalmia producing cause such as fluidity tear generates reduction, mucous secretion exception and tarsus at present
Gland dysfunction etc., leads to the absolute and relative shortage of the fluidity ingredient of tear film, ocular tear abnormal distribution, and tear evaporation increases
And it moisten cornea and conjunctiva cannot normally and the general name that ocular epithelium does the one group of clinical disease become occur.Symptom passes through
Treatment can be alleviated, it can be difficult to curing completely, common treatment means are soaked using common water borne eye drops, lubricate eye
Ball, to alleviate ophthalmic uncomfortable；Or tear substitutes artificial tears are applied, but their common disadvantages are that preparation is in ocular
Residence time is short, eliminates quickly, bioavilability is not high.In recent years, with the hair of the electronic products such as TV, computer, mobile phone
Exhibition, eye health are increasingly becoming the social concern to become increasingly conspicuous.Electronic product is used for a long time, patients with dry eye becomes in cumulative year after year
Gesture and to become younger development, in time prevention alleviate xerophthalmia, can reduce ophthalmic uncomfortable.
Nano-carrier currently used for ocular drug delivery mainly has micro emulsion, liposome, lipid cubic crystal, vesica, water-setting
Glue etc..Drug can extend drug in the delay of eye after nano-carrier contains, while promote drug cornea to penetrate, and improve
Its bioavilability.Chitosan is considered as a kind of nontoxic to the human body, nonirritant, polymer of bio-compatible, by
Japan, Italy and Finland's approval are used for food, and U.S. FDA also has been approved by it and is used in wound dressing auxiliary material, have good
Biodegradability, have antibacterial effect, to medicament slow release treatment have certain synergism.Chitosan be in nature only
One alkaline polysaccharide easily forms intramolecular, divides due to containing great amount of hydroxy group, acetylamino, amino groups in its molecular structure
Ammonia key between son is in close crystalline structure, and crystallinity is higher, thus not soluble in water or organic solvent, dissolves in diluted acid, molten
Liquid is in thick.Hydroxyl and amino Nature comparison in chitosan molecule is active, may be trimmed, activates and is coupled.Alginic acid
Sodium is a kind of natural polysaccharide extracted from kelp, passes through (1,4) glucosides by beta-D-mannuronic acid and α-L- guluronic acid
Key links.In aqueous solution, carboxylic ions are negatively charged for sodium alginate, show polyanionic polymer characteristic, and two
Person forms a kind of compound polyelectrolyte for being not dissolved in water by charge interaction.In addition, the two passes through electrostatic interaction, ammonia
The modes such as key effect or crosslinking, form and seep miscellaneous interpenetrating networks, the stability and carrying drug ratio of pharmaceutical carrier can be improved, improve carrier
Mechanical property.
Summary of the invention
The present invention provides the eye sticker and preparation method thereof that nanometer percutaneous technique is used to improve eyes xerophthalmia, and the eye sticker is main
Ingredient is the compositions useful and chitin-sodium alginate nano-carrier for treating xerophthalmia.
Technical solution of the present invention is as follows.
Nanometer percutaneous technique is used to improve the preparation method of the eye sticker of eyes xerophthalmia, includes the following steps:
(1) sodium alginate and calcium chloride are dissolved in distilled water respectively, obtain sodium alginate stock solution and calcium chloride water；
(2) compositions useful is dissolved in sodium alginate stock solution, stirs 0.5-2h；
(3) it will be added in calcium chloride water 30min-60min in step (2) solution under agitation, and continue to stir
15min-60min completes pregelatinized process；
(4) it dissolves chitosan in the acetic acid that 5-20ml mass percent concentration is 1-2%, and it is pre- solidifying that step (3) is added dropwise
In glue, continues to stir 30min-60min, form nano particle；
(5) ultrasonic disperse prevents from assembling, with 10000rpm-15000 centrifugation 20min-60min freeze-drying at powder；
(6) above-mentioned powder is redissolved, and borneol is added and menthol stirs and evenly mixs, filtering, sterilizing obtains eye sticker liquid；
(7) non-woven fabrics is put into the eye sticker liquid that step (6) obtains and is infiltrated, packed, obtain the eye sticker for alleviating xerophthalmia.
In the above method, the compositions useful includes ciclosporin A, epidermal growth factor, vitamin E, lutein, fructus lycii
One or more of extract, cassia seed extract, vitamin A.
In the above method, the total weight based on composition, the vitamin A, vitamin E, ciclosporin A, epidermal growth factor
Son and the mass content of lutein in the composition are respectively 0.01-100%；The wolfberry fruit extract, cassia seed extract it is total
Mass content is 0.01 ~ 15%.
The compositions useful nano-carrier that the present invention wraps up treatment xerophthalmia can transdermal alleviation symptom.Present invention uses
It can degrade in vivo, the chitin-sodium alginate nano-carrier of good biocompatibility is carried in eye sticker, is not only improved
The storage stability of composition, at the same wherein effective component can with slow release, can play further improve xerophthalmia and
The effect of visual fatigue.
Compared with prior art, present invention has an advantage that
Present invention uses what can be degraded in vivo, the chitin-sodium alginate nano-carrier of good biocompatibility is loaded
In the storage stability in eye sticker, not only improving composition, at the same wherein effective component can with slow release, can play into
The effect of one step improvement xerophthalmia and visual fatigue.Effective nano drug-carrying composition can adjust the nerve on eyes and head well,
Muscle, blood vessel promotes the blood circulation on eye and head, thus achieve the purpose that loosen, it is uncomfortable to various eyes, as eyes are dry
The symptoms such as puckery, eye fatigue, hypopsia, photophobia shed tears, myopia, presbyopia, glaucoma, intraocular hypertension, cataract have very
Good alleviation and adjustment effect.
Detailed description of the invention
Fig. 1 is the prepared chitin-sodium alginate nano-carrier grain-size graph come out of real embodiment 3.
Fig. 2 be by nanoparticle cyclosporin A in ultraviolet spectrophotometry detection example 1 at 37 DEG C in pH7.4PBS
Slow release curve graph.
Specific embodiment
The present invention will be further described with reference to embodiments.
Wolfberry fruit extract purchase in the present embodiment buys Yu Langlin in bright woods biological (NAT-115), cassia seed extract
Biological (NAT-041).
Embodiment 1
(1) 0.1g sodium alginate and 0.01g calcium chloride are dissolved in respectively in the distilled water of 10ml.
(2) by 0.5ug epidermal growth factor and 1mg ciclosporin A, 0.05mg wolfberry fruit extract is dissolved in sodium alginate deposit
In liquid, 1h is stirred.
(3) it will be added in calcium chloride water 30min in above-mentioned 2 solution under agitation, and continue to stir 15min
Complete pregelatinized process.
(4) next 0.01g chitosan is dissolved in the acetic acid (mass percent concentration 2%) of 10ml, and added dropwise
Enter in above-mentioned 3 pregel, continues to stir 30min, form nano particle.
(5) ultrasonic disperse 20min prevents from assembling, with 11000rpm centrifugation 40min freeze-drying at powder.
(6) above-mentioned powder is redissolved, and borneol is added and menthol stirs and evenly mixs, filtering, sterilizing obtains eye sticker liquid.
(7) non-woven fabrics is put into the eye sticker liquid that step (6) obtains and is infiltrated, packed, obtain the eye for alleviating xerophthalmia
Patch.
Fig. 2 be by nanoparticle cyclosporin A in ultraviolet spectrophotometry detection example 1 at 37 DEG C in pH7.4PBS
Slow release curve graph, cyclosporine can realize that slow release, the cumulative release of 30h are 40% in nano-carrier.
Embodiment 2
(1) 0.1g sodium alginate and 0.01g calcium chloride are dissolved in respectively in the distilled water of 10ml.
(2) 0.05mg wolfberry fruit extract, 0.1mg cassia seed extract and 1mg ciclosporin A are dissolved in sodium alginate deposit
In liquid, 1h is stirred.
(3) it will be added in calcium chloride water 30min in above-mentioned 2 solution under agitation, and continue to stir 15min
Complete pregelatinized process.
(4) next 0.01g chitosan is dissolved in the acetic acid (2%) of 10ml, and is added dropwise in above-mentioned 3 pregel,
Continue to stir 30min, forms nano particle.
(5) ultrasonic disperse 30min prevents from assembling, with 11000rpm centrifugation 40min freeze-drying at powder.
(6) above-mentioned powder is redissolved, and borneol is added and menthol stirs and evenly mixs, filtering, sterilizing obtains eye sticker liquid.
(7) non-woven fabrics is put into the eye sticker liquid that step (6) obtains and is infiltrated, packed, obtain the eye for alleviating xerophthalmia
Patch.
Embodiment 3
For improving the eye sticker nanometer percutaneous technique of eyes xerophthalmia
(1) 0.1g sodium alginate and 0.01g calcium chloride are dissolved in respectively in the distilled water of 10ml.
(2) by 0.05ug epidermal growth factor, 0.01mg lutein and 1mg vitamin A, the dissolution of 0.05mg wolfberry fruit extract
In sodium alginate stock solution, 1h is stirred.
(3) it will be added in calcium chloride water 30min in above-mentioned 2 solution under agitation, and continue to stir 15min
Complete pregelatinized process.
(4) next 0.02g chitosan is dissolved in the acetic acid (2%) of 10ml, and is added dropwise in above-mentioned 3 pregel,
Continue to stir 30min, forms nano particle.
(5) ultrasonic disperse 10min prevents from assembling, with 11000rpm centrifugation 40min freeze-drying at powder.
(6) above-mentioned powder is redissolved, and borneol is added and menthol stirs and evenly mixs, filtering, sterilizing obtains eye sticker liquid.
(7) non-woven fabrics is put into the eye sticker liquid that step (6) obtains and is infiltrated, packed, obtain the eye for alleviating xerophthalmia
Patch.
Fig. 1 is the prepared chitin-sodium alginate nano-carrier grain-size graph come out of real embodiment 3, it can be seen that partial size exists
190nm or so, PDI 0.1, size is uniform, is uniform dispersion, is easy to Transdermal absorption.
The above embodiment of the present invention be only to clearly illustrate example of the present invention, and not be to the present invention
Embodiment restriction.For those of ordinary skill in the art, it can also make on the basis of the above description
Other various forms of variations or variation.There is no necessity and possibility to exhaust all the enbodiments.It is all of the invention
Made any modifications, equivalent replacements, and improvements etc., should be included in the protection of the claims in the present invention within spirit and principle
Within the scope of.
Claims (4)
1. the preparation method that nanometer percutaneous technique is used to improve the eye sticker of eyes xerophthalmia, which comprises the steps of:
(1) sodium alginate and calcium chloride are dissolved in distilled water respectively, obtain sodium alginate stock solution and calcium chloride water；
(2) compositions useful is dissolved in sodium alginate stock solution, stirs 0.5-2h；
(3) it will be added in calcium chloride water 30min-60min in step (2) solution under agitation, and continue to stir
15min-60min completes pregelatinized process；
(4) it dissolves chitosan in the acetic acid that 5-20ml mass percent concentration is 1-2%, and it is pre- solidifying that step (3) is added dropwise
In glue, continues to stir 30min-60min, form nano particle；
(5) ultrasonic disperse prevents from assembling, with 10000rpm-15000 centrifugation 20min-60min freeze-drying at powder；
(6) above-mentioned powder is redissolved, and borneol is added and menthol stirs and evenly mixs, filtering, sterilizing obtains eye sticker liquid；
(7) non-woven fabrics is put into the eye sticker liquid that step (6) obtains and is infiltrated, packed, obtain the eye sticker for alleviating xerophthalmia.
2. nanometer percutaneous technique is used to improve the preparation method of the eye sticker of eyes xerophthalmia, feature according to claim 1
It is, the compositions useful includes ciclosporin A, epidermal growth factor, vitamin E, lutein, wolfberry fruit extract, cassia seed
One or more of extract, vitamin A.
3. nanometer percutaneous technique is used to improve the preparation method of the eye sticker of eyes xerophthalmia, feature according to claim 2
It is, the total weight based on composition, the vitamin A, vitamin E, ciclosporin A, epidermal growth factor and lutein are in group
The mass content closed in object is respectively 0.01-100%；The wolfberry fruit extract, the gross mass content of cassia seed extract are 0.01
~15%。
4. nanometer percutaneous technique is prepared for improving the eye of eyes xerophthalmia in any one of claim 1 ~ 3 preparation method
Patch.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910225899.XA CN109908328A (en) | 2019-03-25 | 2019-03-25 | Nanometer percutaneous technique is used to improve the eye sticker and preparation method thereof of eyes xerophthalmia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910225899.XA CN109908328A (en) | 2019-03-25 | 2019-03-25 | Nanometer percutaneous technique is used to improve the eye sticker and preparation method thereof of eyes xerophthalmia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109908328A true CN109908328A (en) | 2019-06-21 |
Family
ID=66966585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910225899.XA Pending CN109908328A (en) | 2019-03-25 | 2019-03-25 | Nanometer percutaneous technique is used to improve the eye sticker and preparation method thereof of eyes xerophthalmia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109908328A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114028363A (en) * | 2021-11-25 | 2022-02-11 | 上海婷伊美科技有限公司 | Gold eye patch for xerophthalmia and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999030683A1 (en) * | 1997-12-12 | 1999-06-24 | Roland Bodmeier | Preparation with a prolonged retention time at the site of application |
| CN107260808A (en) * | 2017-05-31 | 2017-10-20 | 北京市眼科研究所 | A kind of liniment for alleviating visual fatigue and its production and use |
| WO2018054077A1 (en) * | 2016-09-26 | 2018-03-29 | Reyoung (Suzhou) Biology Science & Technology Co., Ltd | Composition for treating ocular diseases and methods of usage and making |
| CN107998399A (en) * | 2017-12-22 | 2018-05-08 | 北京诺康达医药科技有限公司 | A kind of cyclosporine compound eye drops and preparation method thereof |
| CN108541866A (en) * | 2018-04-26 | 2018-09-18 | 福州大学 | A kind of cinnamic acid-sodium alginate-chitosan nanoparticle and preparation method thereof |
| CN109432234A (en) * | 2018-12-28 | 2019-03-08 | 张鸣岐 | A kind of antibacterial eyeshield eye sticker |
-
2019
- 2019-03-25 CN CN201910225899.XA patent/CN109908328A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999030683A1 (en) * | 1997-12-12 | 1999-06-24 | Roland Bodmeier | Preparation with a prolonged retention time at the site of application |
| WO2018054077A1 (en) * | 2016-09-26 | 2018-03-29 | Reyoung (Suzhou) Biology Science & Technology Co., Ltd | Composition for treating ocular diseases and methods of usage and making |
| CN107865821A (en) * | 2016-09-26 | 2018-04-03 | 瑞阳(苏州)生物科技有限公司 | A kind of preparation for preventing or treating CNV and formed |
| CN107260808A (en) * | 2017-05-31 | 2017-10-20 | 北京市眼科研究所 | A kind of liniment for alleviating visual fatigue and its production and use |
| CN107998399A (en) * | 2017-12-22 | 2018-05-08 | 北京诺康达医药科技有限公司 | A kind of cyclosporine compound eye drops and preparation method thereof |
| CN108541866A (en) * | 2018-04-26 | 2018-09-18 | 福州大学 | A kind of cinnamic acid-sodium alginate-chitosan nanoparticle and preparation method thereof |
| CN109432234A (en) * | 2018-12-28 | 2019-03-08 | 张鸣岐 | A kind of antibacterial eyeshield eye sticker |
Non-Patent Citations (2)
| Title |
|---|
| BORGES,O等: ""Uptake studies in rat Peyer"s patches, cytotoxicity and release studies of alginate coated chitosan nanoparticles for mucosal vaccination"", 《 JOURNAL OF CONTROLLED RELEASE》 * |
| 陈敏等: ""环孢素A微乳巴布膏眼贴的制备及体外透皮实验"", 《中国组织工程研究》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114028363A (en) * | 2021-11-25 | 2022-02-11 | 上海婷伊美科技有限公司 | Gold eye patch for xerophthalmia and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pahuja et al. | Ocular drug delivery system: a reference to natural polymers | |
| Silva et al. | New nanoparticles for topical ocular delivery of erythropoietin | |
| CN103446187B (en) | Pharmaceutical composition of a kind of anti-inflammation detumescence and its production and use | |
| Naik et al. | Mucoadhesive micro-/nano carriers in ophthalmic drug delivery: an overview | |
| JPH11510497A (en) | Formulations containing O-carboxyalkyl chitosan and methods of use in the ophthalmic field | |
| US20150031629A1 (en) | Ophthalmic formulation derived from silk protein | |
| Chandra et al. | Insight on updates in polysaccharides for ocular drug delivery | |
| WO2020222195A1 (en) | Dissolvable polymeric eye inserts and method of using same | |
| CN110496215A (en) | A kind of aqueous ophthalmic solution and preparation method thereof for treating presbyopia | |
| Yu et al. | Polysaccharide-based nanomaterials for ocular drug delivery: A perspective | |
| CN109908328A (en) | Nanometer percutaneous technique is used to improve the eye sticker and preparation method thereof of eyes xerophthalmia | |
| CN110090294A (en) | Ophthalmic composition with improved dry-run protection and reservation | |
| Cheng et al. | Zinc insulin hexamer loaded alginate zinc hydrogel: Preparation, characterization and in vivo hypoglycemic ability | |
| Modi et al. | Polysaccharide-based nanogels and ocular drug delivery: The emerging nanocarrier for crossing blood retinal barrier | |
| WO2022106676A1 (en) | Chitosan-based beads, and preparation, compositions and uses thereof | |
| CN107075174A (en) | Heat sterilization preparation and its preparation technology comprising chitosan | |
| CN109481403A (en) | A kind of chitosan-modified triamcinolone acetonide acetate liposome and preparation method | |
| Burgalassi et al. | Larch arabinogalactan for dry eye protection and treatment of corneal lesions: investigations in rabbits | |
| Zambito et al. | Polysaccharides as excipients for ocular topical formulations | |
| CN105983004A (en) | Composition capable of alleviating asthenopia and preparation method | |
| EP2346513A1 (en) | Compositions comprising polymers having amino sugar units and methods of making and using same | |
| CN101543509B (en) | Ophthalmic gel containing chondroitin sulfate and method for preparing same | |
| CN114099645A (en) | Pharmaceutical composition for repairing corneal tissue by using insulin nano system and application thereof | |
| FR2927255A1 (en) | BIOCOMPATIBLE INJECTABLE PRODUCTS WITH ZINC RELEASE AND / OR ZINC SACCHARIDE SALT AND USES THEREOF. | |
| CN102198087B (en) | Preservative-free ophthalmic in-situ gelling agent and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190621 |